Hermetica Superfood Encyclopedia
The Short Answer
Eckol is a closed-chain trimer of phloroglucinol and a principal eckol-type phlorotannin from Ecklonia cava that scavenges reactive oxygen species, suppresses NF-κB/MAPK inflammatory signaling, inhibits caspase-9/3-mediated apoptosis, and blocks the Alzheimer's-related enzyme BACE1 (IC50 12.20 µM). Preclinical data demonstrate that eckol reduces Aβ25-35-induced ROS by more than 3-fold and attenuates TNF-α and IL-1β elevations (>4-fold reduction at 50 µM, p < 0.001) in neuronal PC12 cells, positioning it as a candidate neuroprotective and anti-inflammatory marine bioactive pending human clinical validation.
CategoryExtract
GroupMarine-Derived
Evidence LevelPreliminary
Primary Keywordeckol phlorotannin benefits
Eckol — botanical close-up
Health Benefits
**Antioxidant Defense**
Eckol and co-occurring phlorotannins (dieckol, 8,8′-bieckol) concentration-dependently attenuate Aβ25-35-induced ROS accumulation by more than 3-fold in PC12 neuronal cells at 1 µM (p < 0.05), likely through direct radical scavenging via multiple hydroxyl groups on the phloroglucinol backbone.
**Neuroprotection**: By inhibiting BACE1 (IC50 12
20 µM for eckol vs. 2.21 µM for dieckol) and reducing amyloid-beta-induced oxidative and inflammatory insults, eckol-type phlorotannins from E. cava may attenuate neurodegeneration-associated cellular damage, as demonstrated in Aβ25-35-challenged PC12 cell models.
**Anti-Inflammatory Activity**
Eckol displays the strongest reduction of TNF-α and IL-1β cytokine elevations (>4-fold suppression at 50 µM, p < 0.001) among tested phlorotannins, and co-occurring dieckol and 8,8′-bieckol downregulate iNOS and COX-2 protein expression (p < 0.01–0.001) in lipopolysaccharide-stimulated macrophage and neuronal models.
**Apoptosis Inhibition**: Phlorotannins from E
cava suppress caspase-9 and caspase-3 activation in Aβ25-35-challenged PC12 cells, with significant effects observed at 10 µM for dieckol and 8,8′-bieckol and at 50 µM for eckol (p < 0.05), thereby protecting neurons from mitochondria-mediated programmed cell death.
**NF-κB and MAPK Pathway Modulation**
Eckol-type phlorotannins attenuate phosphorylation of p65 and IκB within the NF-κB cascade and dampen MAPK signaling arms (p < 0.05–0.001), reducing the transcriptional drive behind pro-inflammatory cytokine and enzyme production in cellular models of neuroinflammation.
**Anti-Diabetic Potential**: Phlorotannins from E
cava, including eckol, are reported to inhibit α-glucosidase and α-amylase enzymatic activity, slowing postprandial carbohydrate digestion; however, compound-specific IC50 values and human pharmacodynamic data remain to be established in controlled clinical settings.
**Cardiovascular Antioxidant Support**
The dense polyphenolic architecture of eckol (multiple catechol/phloroglucinol units) confers metal-chelating and lipid-peroxidation-inhibiting capacity in vitro, suggesting potential cardioprotective roles, though direct cardiovascular endpoint studies in humans are currently absent from the published literature.
Origin & History
Natural habitat
Ecklonia cava is a perennial brown macroalga (Laminariales order) native to the subtidal zones of the Pacific Ocean, predominantly harvested from coastal waters surrounding South Korea, Japan, and China at depths of 1–10 meters. It thrives in cold-to-temperate, nutrient-rich marine environments with high wave exposure, anchoring to rocky substrates via holdfasts. Unlike terrestrial plants, E. cava is not traditionally cultivated on land but is commercially harvested from wild populations and increasingly farmed via marine aquaculture operations, particularly in South Korean coastal regions where it has been used as a food source and functional ingredient.
“Ecklonia cava has been consumed as a food ingredient in East Asian coastal communities—particularly in South Korea and Japan—for centuries, prepared in soups, salads, and side dishes (known locally as 'gapsam' in Korean), primarily valued for its mineral content and umami flavor rather than recognized pharmacological properties. The isolation and characterization of phlorotannins including eckol as discrete bioactive constituents is a product of modern analytical chemistry beginning in the late 20th century, with systematic phytochemical investigation intensifying from the 1990s onward following advances in HPLC, NMR, and mass spectrometry techniques. Unlike terrestrial polyphenol-rich botanicals such as green tea or ginkgo, E. cava carries no documented role in classical East Asian pharmacopoeias (e.g., the Chinese Pharmacopoeia or Korean traditional medicine texts) specifically ascribing therapeutic functions to its phlorotannin fraction. The contemporary positioning of eckol and related phlorotannins is therefore entirely within the modern functional food and nutraceutical paradigm, driven by academic research output from South Korean and Japanese institutions rather than by any established ethnopharmacological tradition.”Traditional Medicine
Scientific Research
The current evidence base for eckol consists entirely of preclinical research—principally in vitro cell assays using PC12 neuronal cells and macrophage lines, complemented by rat pharmacokinetic studies—with no published randomized controlled trials or observational human studies reporting specific sample sizes or clinical effect sizes for eckol as an isolated compound. In vitro studies have reported statistically significant outcomes (p < 0.05 to p < 0.001) for ROS suppression, cytokine reduction, BACE1 inhibition, and NF-κB pathway attenuation, providing mechanistic plausibility but not translational proof. Rat intravenous pharmacokinetic data for the closely related dieckol and 8,8′-bieckol (10 mg/kg EK-ECP) show plasma detectability up to 36 hours post-dose (clearance 193 and 162 mL/h/kg respectively; Vz 3350 and 2200 mL/kg), indicating reasonable systemic exposure in rodents, while phlorofucofuroeckol A clears substantially faster (clearance ~84,000 mL/h/kg, detectable only to 2 h). Given the absence of human trials, the existing body of work—while mechanistically informative and methodologically sound within its preclinical scope—cannot support clinical efficacy claims, and translation to human supplemental dosing recommendations remains premature.
Preparation & Dosage
Traditional preparation
**Phlorotannin-Rich Seaweed Extract (ECE/EK-ECP)**
10 mg/kg IV as a pharmacokinetic reference dose
Standardized extracts confirmed via HPLC/NMR to ≥91% total phlorotannin content; no validated human oral dose established; rodent studies used .
**Crude E. cava Powder**
Contains 0.6–3.1% total phlorotannins by dry weight; used in food-grade nutraceutical formulations at gram-level servings, though eckol-specific bioavailability from this matrix is undetermined.
**HPLC-Isolated Eckol Fractions**
Research-grade isolates used in cell-based studies at 1–50 µM concentrations; no current commercial supplement provides pure eckol at these verified concentrations for human use.
**Dieckol-Enriched Bioprocessed Extracts**
Bioprocessing techniques (enzymatic or fermentation-assisted) can increase dieckol yield relative to crude extraction; dieckol may be preferred over eckol for BACE1 inhibition given its superior IC50 (2.21 µM vs. 12.20 µM).
**Timing and Form Notes**
Oral bioavailability is presumed low based on rodent PK data showing rapid clearance of some phlorotannins (PFF-A detectable only to 2 h post-IV dose); lipid-based or nanoparticle delivery systems are under investigation to enhance gastrointestinal stability and absorption but are not yet commercially standardized.
Nutritional Profile
Ecklonia cava as a whole algal biomass provides iodine, iron, calcium, magnesium, and dietary fiber typical of brown macroalgae, but the pharmacologically relevant fraction is the phlorotannin pool comprising 0.6–3.1% dry weight. Within the phlorotannin fraction, dieckol is the most abundant compound in high-polarity extracts (confirmed as the dominant HPLC peak at 15.65 min retention), followed by 8,8′-bieckol and phlorofucofuroeckol A (PFF-A, 602.06 g/mol), with eckol (a closed-chain trimer, appearing at 10.450 min) present as a quantitatively minor but bioactively significant constituent. Molecular weights span from approximately 372 g/mol (eckol trimer) to 974 g/mol for hexameric phlorotannins such as PHB and PPB, and this size variation directly influences intestinal permeability, protein-binding affinity, and renal clearance. Bioavailability of all eckol-type phlorotannins from oral ingestion is expected to be substantially limited by their high molecular weight, hydrophilicity, susceptibility to gastric pH degradation, and extensive phase II conjugation in the intestinal wall and liver.
How It Works
Mechanism of Action
Eckol's primary antioxidant mechanism involves direct hydrogen-atom and electron transfer from its multiple hydroxyl-substituted phloroglucinol rings, quenching superoxide, hydroxyl, and peroxyl radicals while also chelating redox-active transition metals that catalyze Fenton-type reactions. At the inflammatory signaling level, eckol and structurally related dieckol attenuate IκB phosphorylation and subsequent nuclear translocation of NF-κB p65, suppressing transcription of iNOS, COX-2, TNF-α, and IL-1β genes; MAPK pathway components (ERK, JNK, p38) are also dampened, reducing a second major inflammatory amplification axis. Eckol inhibits BACE1 (beta-site amyloid precursor protein cleaving enzyme 1) with an IC50 of 12.20 µM and a docking binding energy of −8.3 kcal/mol, limiting amyloidogenic processing of APP and downstream Aβ peptide generation, an effect complemented by co-compound dieckol (IC50 2.21 µM, −13.3 kcal/mol). Collectively, these actions converge to reduce mitochondrial cytochrome-c release, blunt caspase-9 and caspase-3 activation, and preserve cellular viability under amyloid-beta and lipopolysaccharide-induced stress conditions in neuronal and macrophage model systems.
Clinical Evidence
No published human clinical trials specifically investigating eckol as an isolated phlorotannin from Ecklonia cava have been identified in the peer-reviewed literature; all efficacy and mechanistic data originate from in vitro neuronal and macrophage cell models and rodent pharmacokinetic experiments. The most quantified outcomes—including >3-fold ROS attenuation at 1 µM, >4-fold cytokine suppression at 50 µM, BACE1 IC50 of 12.20 µM, and caspase-3/9 inhibition—were generated in PC12 cells challenged with amyloid-beta or lipopolysaccharide, representing high-dose, controlled laboratory conditions not directly predictive of human response. Rat PK studies with the phlorotannin-rich extract EK-ECP establish baseline absorption and distribution parameters but do not address bioavailability from oral nutraceutical formulations in humans, where first-pass metabolism and gut-microbial biotransformation are expected to substantially alter circulating concentrations. Confidence in clinical benefit remains low pending adequately powered Phase I/II trials that define safe oral doses, achievable plasma concentrations of eckol in humans, and measurable downstream biomarker responses.
Safety & Interactions
No adverse effects, hepatotoxicity, or dose-limiting toxicities were reported in the preclinical cell culture or rodent pharmacokinetic studies reviewed, and GRAS-approved solvents used during extraction indicate low residual solvent risk in commercial preparations; however, the absence of reported side effects in animal models does not establish human safety, and formal toxicological studies (NOAEL/LOAEL determinations, subchronic or chronic rodent feeding studies) specific to isolated eckol are not yet publicly available. Drug interaction data for eckol are currently nonexistent in the published literature; based on its structural class as a polyphenol with anti-inflammatory and enzyme-inhibiting properties, theoretical interactions with anticoagulants (due to COX pathway modulation), immunosuppressants, and anti-diabetic medications (due to α-glucosidase inhibition) warrant investigation before co-administration guidance can be provided. Individuals with known iodine sensitivity or thyroid disorders should exercise caution with whole E. cava-based products given the alga's naturally high iodine content, though this concern applies less to purified eckol isolates. Pregnancy and lactation safety data are entirely absent, and use during these periods cannot be recommended until adequate safety studies are completed.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Ecklonia cava phlorotannineckol-type phlorotanninmarine polyphenol eckolECE phlorotanningapsam extract
Frequently Asked Questions
What is eckol and what makes it different from other phlorotannins in Ecklonia cava?
Eckol is a closed-chain trimer of phloroglucinol and one of the principal eckol-type phlorotannins isolated from the brown macroalga Ecklonia cava. Unlike the more abundant dieckol (a hexameric compound, 742.07 g/mol) or phlorofucofuroeckol A, eckol is structurally smaller and appears as a minor but bioactively significant HPLC peak (retention time 10.450 min); it shows the strongest suppression of TNF-α and IL-1β among tested phlorotannins at 50 µM (p < 0.001), though dieckol surpasses it in BACE1 enzyme inhibition (IC50 2.21 µM vs. eckol's 12.20 µM).
What does the research say about eckol for brain health and Alzheimer's disease?
Preclinical in vitro studies using PC12 neuronal cells demonstrate that eckol reduces amyloid-beta (Aβ25-35)-induced reactive oxygen species by more than 3-fold at concentrations as low as 1 µM and suppresses pro-inflammatory cytokines TNF-α and IL-1β by more than 4-fold at 50 µM (p < 0.001). Eckol also inhibits BACE1—the enzyme responsible for generating Aβ peptides from amyloid precursor protein—with an IC50 of 12.20 µM and a molecular docking energy of −8.3 kcal/mol, suggesting mechanistic relevance to Alzheimer's pathology; however, no human clinical trials have been conducted, so these findings remain exploratory.
What is the recommended dosage of eckol or Ecklonia cava extract for humans?
No validated human supplemental dose for isolated eckol has been established in peer-reviewed clinical trials as of the current literature. Rodent pharmacokinetic studies employed 10 mg/kg of a phlorotannin-rich extract (EK-ECP) delivered intravenously, which is not directly translatable to oral human dosing. Commercial E. cava-based nutraceuticals typically provide whole-extract formulations standardized to total phlorotannin content (0.6–3.1% in crude material; up to 91% in concentrated extracts), but without human dose-finding studies, any specific milligram recommendation would be speculative.
Is eckol from Ecklonia cava safe to take as a supplement?
Available preclinical data—including rat pharmacokinetic experiments and cell-based assays—have not identified cytotoxicity or organ toxicity signals for eckol or E. cava phlorotannin extracts at studied concentrations, and GRAS-approved extraction solvents suggest low processing-related risk. However, formal human safety studies establishing a no-observed-adverse-effect level (NOAEL), drug interaction profiles, and pregnancy safety data are absent. Individuals with thyroid conditions or iodine sensitivity should be cautious with whole-algae products due to E. cava's high intrinsic iodine content, though this is less relevant to purified phlorotannin isolates.
How does eckol work as an anti-inflammatory compound?
Eckol exerts anti-inflammatory effects primarily by blocking the NF-κB signaling pathway—specifically attenuating phosphorylation of IκB and the p65 subunit, which prevents nuclear translocation of this transcription factor and subsequent upregulation of iNOS, COX-2, TNF-α, and IL-1β genes (p < 0.05–0.001 in cell studies). Additionally, eckol dampens MAPK signaling cascades (including ERK, JNK, and p38 arms), which serve as a parallel amplification route for inflammatory gene expression. At 50 µM, eckol demonstrates the strongest reduction of TNF-α and IL-1β among the major E. cava phlorotannins tested in Aβ25-35-challenged PC12 neuronal cells.
How does eckol compare to dieckol and 8,8'-bieckol in terms of antioxidant potency?
While eckol is the primary phlorotannin studied in Ecklonia cava, it works synergistically with dieckol and 8,8'-bieckol, which are co-occurring compounds in the extract. Research shows that these phlorotannins work together to provide concentration-dependent antioxidant effects, reducing ROS accumulation by more than 3-fold in neuronal cells at 1 µM. The combination of all three compounds appears more effective than eckol alone, making whole Ecklonia cava extract more beneficial than isolated eckol.
What is the bioavailability difference between isolated eckol and whole Ecklonia cava extract?
Whole Ecklonia cava extract containing eckol and its companion phlorotannins (dieckol and 8,8'-bieckol) may offer superior bioavailability compared to isolated eckol due to synergistic absorption mechanisms and reduced likelihood of rapid metabolism. The multiple hydroxyl groups on the phloroglucinol backbone of these compounds support cellular uptake, though absorption can be enhanced when taken with fat-containing meals. Most research demonstrating neurological benefits uses standardized Ecklonia cava extract rather than pure eckol, suggesting the whole extract formulation may be more bioavailable in practice.
Does eckol from Ecklonia cava interact with Alzheimer's medications or cholinesterase inhibitors?
Eckol inhibits BACE1 (β-secretase), a key enzyme in amyloid-beta production, which is the same therapeutic target as some Alzheimer's drugs, so concurrent use warrants medical oversight to avoid over-suppression of necessary proteolytic pathways. While direct drug-drug interactions haven't been extensively documented, the antioxidant and anti-inflammatory properties of eckol may complement standard Alzheimer's treatments rather than interfere. Anyone taking prescription Alzheimer's medications should consult their healthcare provider before adding Ecklonia cava supplements to ensure safety and appropriate dosing.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w eckol-phlorotannin-ecklonia-cava curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
